Drug updated on 9/14/2023

Dosage FormInjection (intravenous; : 300 mg/15 mL (20 mg/mL))
Drug ClassIntegrin receptor antagonist
Ongoing and
Completed Studies


  • For the treatment of relapsing forms of multiple sclerosis, to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults. TYSABRI increases the risk of PML.
  • For inducing and maintaining clinical response and remission in adult patients with moderately to severely active Crohn’s disease with evidence of inflammation who have had an inadequate response to, or are unable to tolerate, conventional CD therapies and inhibitors of TNF-α.